Physician profile
Umesh Katdare
NPI 1447255898
$27,319.78
in general payments reported to CMS, 2019-2025
41 companies · $2,947 in 2025
The $2,947 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,360 · 2020: $2,142 · 2021: $6,248 · 2022: $6,050 · 2023: $3,305 · 2024: $3,268 · 2025: $2,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,520.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,788.60 | 2019-2025 | Jardiance |
| Abbott Laboratories | $2,669.06 | 2019-2025 | Aveir, Dragonfly Opstar, Amplatzer Amulet |
| Boston Scientific Corporation | $2,656.10 | 2019-2024 | Watchman Flx, Watchman Access System, Resonate El Icd Vr |
| Janssen Pharmaceuticals, INC | $2,569.96 | 2019-2024 | Xarelto |
| Medtronic, INC. | $2,363.44 | 2021-2025 | Cobalt Dr Mri Surescan, Claria Mri Quad Crt-D Surescan, Onyx Frontier |
| Abiomed | $2,212.06 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,573.47 | 2019-2025 | |
| Amgen INC. | $1,094.84 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,071.64 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $732.93 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $705.96 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $700.64 | 2020-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $586.97 | 2022-2025 | |
| Cvrx, INC. | $415.48 | 2021-2024 | Barostim Neo System |
| Medtronic Vascular, INC. | $407.05 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $394.71 | 2024-2025 | |
| Amarin Pharma, INC. | $330.07 | 2019-2022 | |
| Pfizer INC. | $298.73 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.71 | 2019-2023 | Lifevest |
| Cardiovascular Systems INC. | $154.81 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $133.07 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Mannkind Corporation | $124.98 | 2021 | |
| Penumbra, INC. | $110.69 | 2021 | |
| Azurity Pharmaceuticals, INC. | $81.98 | 2023-2025 | Edarbi, Edarbyclor |
| Tactile Systems Technology INC | $78.34 | 2020-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Lexicon Pharmaceuticals, INC. | $73.37 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $70.21 | 2024-2025 | Optimizer |
| Bridgebio Pharma, INC. | $66.44 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $61.04 | 2019 | |
| Althera Pharmaceuticals LLC | $55.70 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $54.88 | 2019-2022 | |
| Shockwave Medical, INC | $50.11 | 2023-2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Arbor Pharmaceuticals, INC. | $45.08 | 2019-2020 | |
| Esperion Therapeutics, INC. | $42.28 | 2020-2021 | |
| Atricure, INC. | $39.82 | 2023 | |
| Vifor Pharma, INC. | $39.20 | 2019-2021 | |
| Lilly USA, LLC | $32.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.45 | 2019-2021 | |
| Scpharmaceuticals INC. | $17.63 | 2023 | |
| Medicure Pharma INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21.28 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umesh Katdare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.